Teva Pharmaceutical Industries (TEVA) Raw Materials (2012 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Raw Materials for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2018.

• For the quarter ending Q4 2018, Raw Materials fell 8.67% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2018 stood at $1.3 billion (down 8.67% YoY), and the FY2018 full-year result was $1.3 billion, down 8.67% from the prior year.
• Raw Materials eased to $1.3 billion in Q4 2018 per TEVA's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Raw Materials topped out at $1.7 billion in Q3 2016 and bottomed at $1.2 billion in Q4 2015.
• Historically, Raw Materials has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2014.
• The sharpest annual moves came in 2015 and 2016: Raw Materials dropped 21.67% in 2015, then jumped 33.89% in 2016.
• Over 5 years, Raw Materials stood at $1.3 billion in 2014, then retreated by 6.57% to $1.2 billion in 2015, then advanced by 15.9% to $1.4 billion in 2016, then climbed by 4.98% to $1.5 billion in 2017, then fell by 8.67% to $1.3 billion in 2018.
• According to Business Quant data, Raw Materials over the past three periods registered $1.3 billion, $1.4 billion, and $1.4 billion for Q4 2018, Q3 2018, and Q2 2018 respectively.